Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting Nov 4 Written by Guest User https://investors.citytx.com/news-releases/news-release-details/phase-1-data-city-fxi-rnai-therapeutic-candidate-thromboembolic Press Release Guest User Next Next City Therapeutics to Present at Upcoming November Investor Conferences
Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting Nov 4 Written by Guest User https://investors.citytx.com/news-releases/news-release-details/phase-1-data-city-fxi-rnai-therapeutic-candidate-thromboembolic Press Release Guest User
